| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-08-01 | Apeiron Biologics (Austria) Rentschler Biotechnologie (Germany) | APN311 | neuroblastoma | manufacturing |
Cancer - Oncology | Production agreement |
| 2013-08-01 | Vivus (USA - CA) Sanofi (France) | avanafil | production manufacturing |
Technology - Services | Production agreement | |
| 2013-07-31 | Boehringer Ingelheim (Germany) Polyphor (Switzerland) | identification and optimization of novel macrocyclic drug candidates addressing therapeutic targets selected by Boehringer Ingelheim | undisclosed | R&D |
undisclosed | Licensing agreement |
| 2013-07-31 | Cancer Research Technology (CRT) (UK) The Institute of Cancer Research (UK) Merck Serono (Germany) | anticancer drugs that block the WNT signalling pathway and biomarkers | R&D development |
Cancer - Oncology | R&D agreement | |
| 2013-07-30 | BioWa (Japan) Lonza (Switzerland) Pfizer (USA - NY) | POTELLIGENT® CHOK1SV Cell Line | licensing |
Licensing agreement | ||
| 2013-07-30 | MDX Health (Belgium) - MultiPlan (USA) | ConfirmMDx™ for prostate cancer test | prostate cancer | Cancer - Oncology | Collaboration agreement | |
| 2013-07-30 | MDX Health (Belgium) - Three Rivers Provider Network (TRPN) (USA) | ConfirmMDx™ for prostate cancer test | prostate cancer | Cancer - Oncology | Commercialisation agreement | |
| 2013-07-30 | KU Leuven (Belgium) Pharmabs (Belgium) FIT Biotech (Finland) | novel immunotherapeutics | licensing |
Cancer - Oncology - Infectious diseases | Licensing agreement | |
| 2013-07-30 | Antitope,wholly owned subsidiary of PolyTherics (UK) ChemomAb (Israel) | therapeutic antibodies | inflammatory diseases | R&D |
Inflammatory diseases | R&D agreement |
| 2013-07-30 | Nerviano Medical Sciences (Italy) Servier (France) | compounds inhibiting the protein kinase TTK/MPS1 | development |
Cancer - Oncology | Development agreement | |
| 2013-07-30 | Abcodia (UK) Cellmid (Australia) | midkine (heparin-binding growth factor) | colorectal cancer | collaboration |
Cancer - Oncology | Collaboration agreement |
| 2013-07-29 | Adocia (France) Eli Lilly (USA) | new formulation of a fast-acting insulin analog | development |
Metabolic diseases | Termination of an agreement | |
| 2013-07-29 | MDX Health (Belgium) - Bostwick Laboratories (USA) | ConfirmMDx™ for prostate cancer test | prostate cancer | commercialisation |
Cancer - Oncology | Commercialisation agreement |
| 2013-07-29 | MedImmune (USA - global biologics arm of AstraZeneca (UK) Kolltan (USA) | monoclonal antibody targeting the Her3 receptor tyrosine kinase | licensing |
undisclosed | Licensing agreement | |
| 2013-07-26 | GSK (UK) Adimab (USA - NH) | licensing |
Technology - Services | Licensing agreement | ||
| 2013-07-26 | Chiesi Farmaceutici (Italy) Cerespir (USA) | CHF 5074 | mild cognitive impairment (MCI) | development |
Neurodegenerative diseases - CNS diseases | Development agreement |
| 2013-07-25 | Teva Pharmaceuticals (Israel) Lonza (Switzerland) | biosimilars | joint-venture |
Termination of an agreement | ||
| 2013-07-25 | GE Healthcare (USA) Eurofins Scientific (Luxembourg) | Cytiva™ Cardiomyocytes | licensing |
Technology - Services | Licensing agreement | |
| 2013-07-24 | Qiagen (The Netherlands) Exosome Diagnostics (USA) | biofluid sample preparation kits for personalized healthcare research | development |
Development agreement | ||
| 2013-07-24 | ImmunID (France) | nomination |
Diagnostic - Cancer - Oncology | Nomination |
